Beiersdorf and Macro Biologics, Inc. are partnering to develop biodegradable antimicrobial peptides — a market that Data Bridge Research projects will grow to reach US $7.85 billion by 2029. In addition, Beiersdorf will join Macro Biologics as an investor through its Oscar & Paul Corporate Venture Capital Unit.
Per Beiersdorf, the arrangement draws on Macro Biologics’ expertise in antimicrobial research in skin and health care. In particular, the collaboration will focus on applying Macro Biologics’ nature-inspired Amicidins to Beiersdorf’s product and formula development.
Amicidins for Derm-driven Skin, Health Care
Amicidins, per Macro, are its first class of proprietary macro biologics. Composed of amino acids, the are purpose-built and reportedly effective against a wide variety of bacteria.
According to Beiersdorf, they can help to alleviate or improve skin conditions and are designed for early, local application in the prevention of wound infections.
The joint objective is to create highly effective, safe and sustainable solutions for a variety of applications across Beiersdorf’s brand portfolio, primarily in dermatological skin care and health care.
Continuing Focus on Climate Care
In addition, the partnership will enable Beiersdorf to deliver "transformative and sustainable innovations" to its consumers.
"Through our collaboration with Macro Biologics, we further enhance Beiersdorf’s innovation power in line with our ‘Win with Care’ strategy, as well as our ambition to continue to lead in Climate Care,” emphasized Gitta Neufang, Ph.D., corporate senior vice president global R&D at Beiersdorf. "“We are excited to have found an outstanding partner in this promising field of antimicrobial peptides, who shares our visionary innovation drive..."
Michael Bevilacqua, M.D., Ph.D., CEO and CSO of Macro Biologics, added, “... For Macro, this collaboration is a perfect fit, both from a research and business perspective. Beiersdorf’s deep expertise in product formulation, development and commercialization will empower Amicidins to improve the lives of people in a variety of settings. This partnership is based on shared principles, as we both strive to create sustainable value for people and the environment."
